Chief Commercial Officer · Pacira BioSciences, Inc. (PCRX)

Brendan Teehan

FY2025 is the first fiscal year CompBrief holds for Brendan Teehan as a named executive officer of Pacira BioSciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,007,677

2nd of 5 named executive officers at Pacira BioSciences by FY2025 total.

5 named officers on file for Pacira BioSciences, FY2025

See an example →

What this number hides

The filing gives the total. Pacira BioSciences’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Free

Get Brendan Teehan’s full pay file as a PDF — free

More than this page: up to 10 years of Brendan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Brendan Teehan and every company like it: Velarion Intel, free for 3 days, no card →

Brendan Teehan compensation by year

Pacira BioSciences Summary Compensation Table · the one fiscal year held
In US dollars, as Pacira BioSciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$497,385
Bonus$231,694
Stock awards$1,421,820
Option awards$1,454,193
Non-equity incentive$225,562
Pension and deferred compensation$0
All other$177,023
Total$4,007,677

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Pacira BioSciences, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050353, and prior-year filings.

How this page was built: the Pacira BioSciences, Inc. filed document, accession 0001104659-26-050353. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU54,000$1,397,520—
Option99,500—$26.59

Per the Outstanding Equity Awards at Fiscal Year-End table in Pacira BioSciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Pacira BioSciences’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Frank LeeChief Executive Officer and Director$11,636,917
Brendan Teehan · this pageChief Commercial Officer$4,007,677
Jonathan SloninChief Medical Officer$3,575,922
Kristen WilliamsChief Administrative Officer and Secretary$3,180,476
Shawn CrossChief Financial Officer$1,029,076

The full Pacira BioSciences compensation record

free company brief

This page is one person within Pacira BioSciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Pacira BioSciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Pacira BioSciences's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Pacira BioSciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Brendan Teehan's compensation dossier